Valeant ups the ante

Share this article:

Valeant's effort to take over Allergan got a push Monday with reports that Pershing Square Management, which along with Valeant is looking to take over Allergan, wants shareholders to meet. The Wall Street Journal notes that Valeant wants the meeting to vote out six members of Allergan's board.

The WSJ uncovered the shareholder meeting in a regulatory filing.

Allergan has encouraged shareholders to refuse Valeant's offers, which rose from $49.4 billion on Thursday to $52.7 billion in cash and stock on Friday.

The WSJ says Pershing has not identified the six board members it wants to show the door, but said Pershing needs support from shareholders who represent a total of 25% of the company's stock for the meeting to occur.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Apple selfies spur diabetes donations

Jazz apples has launched a Crunch to Contribute campaign to raise money for one of two diabetes associations.

Baxter seeks Cambridge, Mass. HQ

Illinois may be tempted to offer tax incentives for the firm to stay put.

FDA wants Alexion to clean up

FDA inspectors have cited the manufacturer of the rare-disease drug Soliris (eculizumab) for poor manufacturing practices.